The effective rate of two doses of Pfizer in preventing delta mutation was 88%, while the effective rate of two doses of AstraZeneca was 67%.

Two doses of Pfizer or AstraZeneca’s COVID-19 vaccine are almost the same Effective against the highly spreading variant of Delta coronavirus According to a new study, because they are the opposite of the previously dominant Alpha variant.

Research published in the New England Journal of Medicine on Wednesday showed that if a person receives two injections, these vaccines are very effective against the Delta variant, which is reflected in the main strain of the world.

The study confirms the headline news about the efficacy of COVID-19 vaccines produced by Pfizer-BioNTech and Oxford-AstraZeneca made by the Department of Public Health (PHE) in May based on real-world data.

The study on Wednesday found that Pfizer’s two doses of Delta variants are 88% effective in preventing symptomatic diseases, while the Alpha variant has an effective rate of 93.7%, roughly the same as previously reported.

Two shots of AstraZeneca vaccine The effective rate for the Delta variant is 67%, which is higher than the 60% originally reported, and the effective rate for the Alpha variant is 74.5%, compared to the initial estimated effective rate of 66%.

British Public Health researchers wrote: “After receiving two doses of the vaccine, there is only a modest difference between the Delta variant and the Alpha variant in terms of vaccine effectiveness.”

Data from Israel estimates that Pfizer’s injections are less effective in symptomatic diseases, although the protection against serious diseases is still high.

PHE has previously stated that the first dose of the two vaccines is approximately 33% effective against symptomatic diseases from the Delta variant.

Other vaccines are also useful

A complete study published on Wednesday found that a dose of Pfizer’s vaccine is 36% effective and a dose of AstraZeneca’s vaccine is approximately 30% effective.

The authors of the study said: “Our discovery of reduced effectiveness after the first dose will support efforts to maximize the two doses of vaccines in vulnerable groups in the context of Delta variants.”

Recently, researchers from the Beth Israel Deaconess Medical Center in Boston, USA also stated that in a laboratory environment, the antibody response of the Johnson & Johnson single-dose vaccine has a very good effect on Delta, and the immune response lasted about eight months.

In June, the manufacturer Russian satellite vaccine It also stated that it is approximately 90% effective against the highly contagious Delta variant.

This vaccine, which Russia is actively selling abroad, was previously found by researchers to be 92% effective against the original coronavirus strain.

The Russian state-owned RIA news agency reported that Denis Logunov, deputy director of the Gamaleya Institute in Moscow, said that the efficacy figures of the Delta variant were calculated based on digital medical and vaccine records.

However, the artificial satellite vaccine has caused some controversy because it was introduced to the public even before the full trial was completed. It is still awaiting approval from the World Health Organization.